Natalia Jiménez, Marta Garcia de Herreros, Òscar Reig, Mercedes Marín-Aguilera, Caterina Aversa, Laura Ferrer-Mileo, Samuel García-Esteve, Leonardo Rodríguez-Carunchio, Isabel Trias, Albert Font, Alejo Rodriguez-Vida, Miguel Ángel Climent, Sara Cros, Isabel Chirivella, Montserrat Domènech, Mariona Figols, Joan Carles, Cristina Suárez, Daniel Herrero Rivera, Enrique González-Billalabeitia, Claudia Cívico, Núria Sala-González, Vicenç Ruiz de Porras, Maria J Ribal, Aleix Prat, Begoña Mellado
BACKGROUND: Androgen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard therapies in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations in the tumor suppressor genes (TSGs) RB1, PTEN, and TP53 are associated with an aggressive evolution and treatment resistance in castration-resistant prostate cancer (CRPC). OBJECTIVE: To study the clinical implications of TSG mRNA expression in mHSPC patients...
March 1, 2024: European Urology Oncology